Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials
- 28 February 2002
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 38, 15-20
- https://doi.org/10.1016/s0959-8049(01)00415-4
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Future treatment options with capecitabine in solid tumoursEuropean Journal Of Cancer, 2002
- Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III StudyJournal of Clinical Oncology, 2001
- Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patientsCancer, 2001
- Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancerAnnals of Oncology, 2001
- Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III StudyJournal of Clinical Oncology, 2001
- Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II StudyJournal of Clinical Oncology, 2000
- Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patientsCancer Chemotherapy and Pharmacology, 2000
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.Journal of Clinical Oncology, 1998
- Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.Journal of Clinical Oncology, 1998